Conjugate Platform for Glioblastoma
Glioblastoma
Pre-clinicalActive
Key Facts
About Diverse Biotech
Diverse Biotech is developing a novel drug conjugate platform that links synthetic cannabinoids (e.g., CBD) to therapeutic payloads to create targeted cancer therapies with improved efficacy and safety. The company's lead focus appears to be on glioblastoma and other cancers, leveraging cannabinoids to enhance blood-brain barrier penetration and localize drug delivery. As a private, pre-revenue company, Diverse Biotech is actively seeking strategic partners and investors to advance its preclinical programs into clinical development. Its leadership combines scientific expertise in chemistry and oncology with business acumen from the Wharton School.
View full company profileTherapeutic Areas
Other Glioblastoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Ropidoxuridine (IPdR) | Shuttle Pharmaceuticals | Phase 2 |
| LNTH-2505 | Lantheus Medical Imaging | Preclinical |
| Leronlimab | CytoDyn | Preclinical |
| Glioblastoma Moonshot | Owkin | Research |
| OPC-001 (PDC Candidate) | Oncopeptides | Phase 1/Window-of-Opportunity |
| αvβ3-targeted ADC | Xintela | Preclinical |
| Undisclosed | Biossil | Phase 2/3 |
| GLIX1 | Hemispherian | Phase 1 |
| InC01 | InCephalo Therapeutics | Pre-clinical |
| Glioblastoma Combination Therapy | JLP Health | Pre-clinical |
| ENV105 | Kairos Pharma | IND Cleared |
| LMP744 | Gibson Oncology | Phase 2 |